SCHEMBL397163

SCHEMBL397163

CN(C)CCN(C)C(=O)c1c[nH]c(C=C2C(=O)Nc3cc(Oc4cccc(NC(=O)c5cccc(C(F)(F)F)c5)c4)ccc32)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 10/20 0.54
NTRK3 Q16288 2/20 0.54
NTRK2 Q16620 8/20 0.48
AKT2 P31751 2/20 0.44
PDPK1 O15530 1/20 0.43
PDK1 Q15118 1/20 0.43
AURKA O14965 1/20 0.42
RAF1 P04049 1/20 0.42
SRC P12931 1/20 0.42
POLB P06746 2/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
AURKB Q96GD4 1/20 0.41
TLK2 Q86UE8 1/20 0.40
KIT P10721 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
FLT3 P36888 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091932 1.00 NTRK1 (0.54) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL399188 0.92 NTRK1 (0.52) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL399187 0.92 NTRK1 (0.52) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL394066 0.90 AKT2 (0.46) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL10091936 0.90 AKT2 (0.46) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL396426 0.90 NTRK1 (0.53) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL10091931 0.90 NTRK1 (0.53) NTRK1NTRK3NTRK2AKT2PDPK1
SCHEMBL395941 0.87 NTRK1 (0.61) NTRK1NTRK3NTRK2AKT2AURKA
SCHEMBL395940 0.87 NTRK1 (0.61) NTRK1NTRK3NTRK2AKT2AURKA
SCHEMBL397475 0.85 NTRK2 (0.53) NTRK1NTRK3NTRK2AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed